Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

NewAmsterdam Pharma Co N.V.

NASDAQ: NAMS · Life Sciences · 5 alerts · CIK 1936258

Share price
$19.46Close, Nov 16
Market cap
$2.33B
Shares outstanding
119.93MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All NewAmsterdam Pharma Co N.V. filings on SEC EDGAR ↗

4:30 PM ET 8-K
Regulatory Approval

NewAmsterdam Pharma Co Regulatory Approval

NewAmsterdam Pharma and its partner Menarini Group received European Commission marketing authorization for Ubeslo (obicetrapib) and Evlarco (obicetrapib/ezetimibe FDC) for the treatment of hypercholesterolaemia, marking the first regulatory approval for obicetrapib worldwide. The approval triggers milestone payments to NewAmsterdam in the mid-teens of millions of euros under its existing licensing agreement with Menarini. The company remains eligible for up to €833 million in total milestones plus tiered double-digit royalties on net sales in Europe.

Counterparty
Menarini Group

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.